Back to results
US 12,649,921 B2Granted
Chemically modified guide RNAs for genome editing with Cas12b
AssigneeVerve Therapeutics, Inc.
InventorsKallanthottathil G. Rajeev, Alexandra Chadwick, Caroline Reiss
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions related to Cas12b guide RNAs. Also provided herein are methods for modifying target polynucleotide sequences and methods of treating or preventing a condition in a subject in need thereof, such as conditions resultant from the expression of ANGPTL3 or mutations thereto.
Claims27
A chemically modified single guide RNA for a Cas12b protein, comprising:
- (i) a spacer sequence complimentary to a polynucleotide sequence located on a strand of a human ANGPTL3 gene, and wherein the spacer sequence is designed to hybridize to the polynucleotide sequence located on the human ANGPTL3 gene, and
- (ii) a scaffold sequence that serves as a binding scaffold for the Cas12b protein,
- wherein the spacer sequence comprises about 10 to about 40 nucleotides in length,
- wherein the scaffold sequence has a nucleotide base sequence, wherein the nucleotide base sequence has at least 90% identity to positions 1 to 97 of SEQ ID NO:
- 1,
- wherein the scaffold sequence comprises a plurality of different chemical modifications,
- wherein the plurality of different chemical modifications are at two or more nucleotide positions selected from positions 1-7, 11, 16-21, 25-31, 39, 42, 45-52, 57-62, 64, 65, and 70-87 as numbered in SEQ ID NO:
- 1 or a corresponding position or combination of corresponding positions thereof, and
- wherein the one or more chemical modifications comprise a 2′-O-methyladenosine, a 2′-O-methylcytidine, a 2′-O-methylguanosine, a 2′-O-methyluridine, a nebularine, a 2′-O-methylnebularine, or a phosphorothioate linkage.
6 more elements
Dependencies are inferred from the claim text.